Seoul Economic Daily EnglishCodex · 实盘不做把握 5/10
北京时间·🕒 发布 16:04:25时区推断·⟳ 抓取 16:52:18·⚡ 决策 07-27 16:53:34 +1m16s·92.0 天前
东亚Socio控股二季度营收和营业利润创季度新高
公司披露二季度合并收入4124亿韩元、营业利润390亿韩元，同比分别增长18.9%和38.3%，主要由东亚制药和Yongma Logis增长驱动。
📄 原文Seoul Economic Daily English↗ 原文
Dong-A Socio Holdings Posts Record Earnings on Subsidiary Growth
Dong-A Socio Holdings posted its largest-ever quarterly earnings, driven by the growth of its key subsidiaries. Dong-A…
不做 东亚Socio控股（000640.KS）
排期内财报披露且缺少一致预期超预期证据，股价披露前两日已明显抢跑，盘后追多edge不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司IR页面显示7月23日已有企业说明会和结算业绩披露预告，说明财报日期本身并非突发。市场反应:000640.KS在7月23日上涨4.55%，7月24日再涨3.98%。
- 公司通过新闻稿披露二季度收入4124亿韩元、营业利润390亿韩元，同比分别增长18.9%和38.3%。市场反应:披露时韩国市场已收盘，无法盘中交易。
- 英文财经媒体同步报道业绩增长由Bacchus和OTC销售带动，同时提到BTgen业绩显著下滑。
- 本次detect来源转述公司二季度创纪录业绩和子公司分项。
关键理由
- 公司披露二季度合并收入4124亿韩元、营业利润390亿韩元，同比分别增长18.9%和38.3%，主要由东亚制药和Yongma Logis增长驱动。
- 东亚制药二季度收入2282亿韩元、Bacchus业务收入878亿韩元，同比增长26.6%，但BTgen收入同比下滑45.2%、营业利润下滑90%，抵消部分质量。
- 该股7月23日至24日已连续上涨约8.7%，且7月23日已有业绩预告/IR日程披露，缺少相对一致预期的明确超预期证据，不适合盘后追财报。
主要风险
- 这是排期内财报披露，若次日高开容易被前两日抢跑资金兑现。
- 缺少公开一致预期对比，无法确认390亿韩元营业利润是否构成真正正向 surprise。
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
未找到可靠公开一致预期；只能确认同比增长，不能确认相对预期的正向 surprise。
检索:Dong-A Socio Holdings Q2 2026 consensus operating profit - 做多前查反向 · 来源 web · 影响 weakens
正式披露前两个交易日股价已累计上涨约8.7%，提高见光死和price-in风险。
检索:000640.KS stock price July 27 2026 Dong-A Socio Holdings 原文 ↗
原文全文
展开原文 · 2,230 字
Dong-A Socio Holdings posted its largest-ever quarterly earnings, driven by the growth of its key subsidiaries.
Dong-A Socio Holdings said on the 27th that it recorded consolidated revenue of 412.4 billion won and operating profit of 39 billion won in the second quarter of this year. This represents increases of 18.9% and 38.4% in revenue and operating profit, respectively, from a year earlier. The operating profit margin improved to 9.4% this year from 8.1% in the same period last year.
The earnings improvement resulted from growth by major consolidated subsidiaries, including Dong-A Pharmaceutical and Yongma Logis, across their respective business areas. Dong-A Pharmaceutical's second-quarter revenue rose 25.7% year-on-year to 228.2 billion won. Stable performances by products including the energy drink "Bacchus," the cold medicine "Panpyrin" and the mouthwash "Garglin" supported the results. In particular, revenue from the Bacchus business division surged 26.6% year-on-year to 87.8 billion won. "Revenue grew significantly thanks to seasonal demand during the election period and strong sales of the new product 'Eolbaksa,'" a company official said. Dong-A Socio Holdings is also proceeding with a merger to absorb Dong-A Pharmaceutical, in which it holds a 100% stake. The merger date is October 1. The company plans to internalize the cash generated by Dong-A Pharmaceutical within the holding company to expand direct investment in new businesses.
The earnings of logistics specialist Yongma Logis also grew on increased logistics volumes from existing clients and the acquisition of new clients. Second-quarter revenue rose 19.7% year-on-year to 120.5 billion won, and operating profit increased 41.6% to 6.9 billion won. "Despite rising fuel costs and logistics material costs, selling and administrative expenses declined, improving profitability," a company official explained.
However, biopharmaceutical contract manufacturing (CMO) subsidiary BTgen (formerly ST Gen Bio) posted weak results as major clients' order schedules were concentrated in the second half of the year. BTgen's second-quarter revenue fell 45.2% year-on-year to 13.7 billion won, and operating profit dropped 90% to 400 million won.
Dong-A Socio Holdings said on the 27th that it recorded consolidated revenue of 412.4 billion won and operating profit of 39 billion won in the second quarter of this year. This represents increases of 18.9% and 38.4% in revenue and operating profit, respectively, from a year earlier. The operating profit margin improved to 9.4% this year from 8.1% in the same period last year.
The earnings improvement resulted from growth by major consolidated subsidiaries, including Dong-A Pharmaceutical and Yongma Logis, across their respective business areas. Dong-A Pharmaceutical's second-quarter revenue rose 25.7% year-on-year to 228.2 billion won. Stable performances by products including the energy drink "Bacchus," the cold medicine "Panpyrin" and the mouthwash "Garglin" supported the results. In particular, revenue from the Bacchus business division surged 26.6% year-on-year to 87.8 billion won. "Revenue grew significantly thanks to seasonal demand during the election period and strong sales of the new product 'Eolbaksa,'" a company official said. Dong-A Socio Holdings is also proceeding with a merger to absorb Dong-A Pharmaceutical, in which it holds a 100% stake. The merger date is October 1. The company plans to internalize the cash generated by Dong-A Pharmaceutical within the holding company to expand direct investment in new businesses.
The earnings of logistics specialist Yongma Logis also grew on increased logistics volumes from existing clients and the acquisition of new clients. Second-quarter revenue rose 19.7% year-on-year to 120.5 billion won, and operating profit increased 41.6% to 6.9 billion won. "Despite rising fuel costs and logistics material costs, selling and administrative expenses declined, improving profitability," a company official explained.
However, biopharmaceutical contract manufacturing (CMO) subsidiary BTgen (formerly ST Gen Bio) posted weak results as major clients' order schedules were concentrated in the second half of the year. BTgen's second-quarter revenue fell 45.2% year-on-year to 13.7 billion won, and operating profit dropped 90% to 400 million won.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。